Generating AI analysis...
Revenue
$13.71B
-7.82% YoY
EPS (Basic)
$0.52
-5.45% YoY
Evidence Layer
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $13.71B | $14.88B | -7.82% |
Cost of Revenue | $2.85B | $3.38B | -15.80% |
Net Income | $2.97B | $3.12B | -4.75% |
EPS (Basic) | $0.52 | $0.55 | -5.45% |
EPS (Diluted) | $0.52 | $0.55 | -5.45% |
SG&A Expense | $3.03B | $3.5B | -13.28% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $208.03B | $221.09B | -5.91% |
Current Assets | $45.86B | $42.41B | +8.12% |
Total Liabilities | $117.39B | $128.54B | -8.67% |
Current Liabilities | $36.45B | $40.5B | -9.99% |
Stockholders' Equity | $90.34B | $92.28B | -2.11% |
Cash & Equivalents | $1.43B | $719M | +98.89% |
Long-Term Debt | $57.64B | $61.31B | -5.98% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $2.33B | $1.09B | +114.22% |
Investing Cash Flow | $3.27B | $1.73B | +89.03% |
Financing Cash Flow | $-5.23B | $-4.93B | -6.00% |
D&A | $1.62B | $1.74B | -6.80% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | 21.6% | — | — |
ROE | 3.3% | — | — |
ROA | 1.4% | — | — |
Current Ratio | $1.258 | — | — |
Debt to Equity | $1.299 | — | — |
Other companies in Pharmaceuticals